Up-Front Payments was ProQR Therapeutics’s largest revenue line in fiscal 2024, bringing in $15.58M of $18.91M (82%).
| Products And Services | FY 2021 | FY 2023 | FY 2024 |
|---|---|---|---|
| Up-Front Payments | $564.00K | $6.00M | $15.58M |
| Milestone Payments | — | — | $2.83M |
| Equity Component | — | $518.00K | $496.00K |
| Equity Consideration | $168.00K | — | — |
| Other Rd Services | $282.00K | — | — |
| Total | $1.01M | $6.51M | $18.91M |
ProQR Therapeutics brought in $18.91M from its three revenue lines in fiscal 2024, the year ended December 31, 2024. ProQR Therapeutics regrouped these revenue lines after fiscal 2023, so the total does not compare directly with that year's $6.51M. Up-Front Payments was the largest at $15.58M (82.4%), ahead of Milestone Payments at $2.83M (14.9%) and Equity Component at $496.00K (2.6%).
Compared with fiscal 2023, Up-Front Payments grew 159.9% to $15.58M, while Equity Component fell 4.2% to $496.00K.
ProQR Therapeutics began breaking out Milestone Payments in fiscal 2024 and Equity Component in fiscal 2023. ProQR Therapeutics stopped reporting Other Rd Services ($282.00K in fiscal 2021) and Equity Consideration ($168.00K in fiscal 2021) as separate revenue lines.
ProQR Therapeutics (PRQR) reports its revenue by products and services. In fiscal 2024, Up-Front Payments was its largest revenue line, bringing in $15.58M (82.4% of the total), followed by Milestone Payments at $2.83M (14.9%).
Up-Front Payments was ProQR Therapeutics' largest revenue line in fiscal 2024, bringing in $15.58M, or 82.4% of the $18.91M total across its three revenue lines.
Every figure comes from ProQR Therapeutics' annual financial filings, as reported. Each line keeps the name ProQR Therapeutics gives it, and years follow its fiscal calendar.
ProQR Therapeutics' revenue by products and services goes back to fiscal 2021, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.